Prevention by XXXX of @entity74 following coronary bypass surgery.

@entity1 @entity8630 @entity301 @entity10719 @entity74 @entity955 @entity1540 @entity943 @entity5069
Seventy-one @entity1 submitted routinely to coronary artery bypass surgery were randomized into 2 groups. Group A (32 @entity1 ) received 24 hr after initiation of surgery an intravenous perfusion of 100 mg of @entity10719 given over 24 hr (22 cases) or 600 mg administered orally (10 cases). On subsequent days, they received 1200 mg of @entity10719 /day orally. Group B (39 @entity1 ) was used as control. The groups were comparable in terms of age, sex, severity of @entity301 , preoperative therapy, duration of extracorporeal circulation, aortic clamping time, and immediate postoperative haemodynamic findings. No @entity1 received digitalis. During hospital stay (10 days), 1 group A @entity1 (3%) and 13 group B @entity1 (33%; P less than 0.001) developed a sustained episode of @entity943 ( @entity955 , @entity5069 or @entity8630 ). The majority of these @entity74 developed between days 2 and 4. On Holter monitoring on days 7-10, @entity1540 (grades IV and V of Lown's classification) were more frequent in group B (65.2%) than in group A (19.3%; P less than 0.001). Haemodynamic measurements taken at rest performed in 27 @entity1 on days 7-10 (16 @entity1 of group A; 11 of group B). No difference was observed between the two groups. @entity10719 is a safe and efficacious drug for the prevention of @entity943 following coronary surgery.
